Share Crohn’s Colitis Foundation Perspectives
Share to email
Share to Facebook
Share to X
By ReachMD
4.5
1313 ratings
The podcast currently has 120 episodes available.
What cultural and cognitive biases might be contributing to health disparities in inflammatory bowel disease (IBD) care? And how can we address them? Find out in the second component of this two-part webinar featuring Drs. Freddy Caldera, Lisa B. Malter, Shubha Bhat, and Stacy Ogbeide. Together, they’ll discuss methods that can help facilitate open communication and strategies for overcoming health disparities in IBD care.
As the landscape of inflammatory bowel disease (IBD) patients is changing, it’s important for healthcare professionals to be aware of the diversity in patient populations and how to best serve them. That’s why the first component of this two-part webinar features gastroenterologist Dr. Lisa B. Malter, who discusses common myths surrounding IBD in certain populations and evidence-based treatment strategies for different patient groups. She’s also joined by Rocio and Tara, two patients living with IBD who share their experiences with IBD management and treatment.
As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.
As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.
Diet and nutrition is known to play a large role in the onset and treatment of IBD. So what were some of the trending sessions focusing on diet and nutrition at the 2022 Crohn’s & Colitis Congress? Join Dr. Jennifer Caudle as she speaks with Dr. Maitreyi Raman to explore the latest research advancements in diet therapies.
What were some of the key takeaways from the 2022 Crohn's & Colitis Congress, and what's in store for next year’s conference? Hear from the incoming 2023 Congress Chair Dr. Peter D. Higgins.
Treating IBD in our pediatric patients can be challenging, which is why creating a strong partnership between care teams and patients’ families is key. Fortunately, that was a central focus of the 2022 Crohn's & Colitis Congress, so to catch the latest updates and strategies for improving IBD care for pediatric patients, tune in to hear Dr. Jennifer Caudle speak with Dr. Ashish Patel.
When patients with moderate ulcerative colitis fail first-line therapy, it's important to know what to do next. And speaking with your patients about their risks and preferences is key. Join us as Dr. Alan Moss shares highlights from his presentation at the 2022 Crohn's & Colitis Congress on treatment considerations for patients with moderate ulcerative colitis.
For patients living with IBD, paying special attention to their nutrition is paramount. So which is more effective for IBD patients with mild-to-moderate symptoms: a Mediterranean style diet or the Special Carbohydrate diet? That’s what the Diets to Induce Remission in Crohn's Disease (DINE-CD) study sought to find out, and now the results are in. Join Dr. Peter Buch as he explores the study's key findings with Dr. Caren Heller, Chief Scientific Officer at the Crohn's and Colitis Foundation.
Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)
Mark T Osterman, Frank I Scott, Franz F Fogt, Erin D Gilroy, Susan Parrott, Joseph Galanko, Raymond Cross, Alan Moss, Hans H Herfarth, Peter D R Higgins
Abstract
Objective: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse.
Design: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley index subcomponents, total Riley score, and basal plasmacytosis.
Results: Only …
The podcast currently has 120 episodes available.